Healthcare / Medical DevicesNasdaqCM
$6.15
-0.05 (-0.77%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-33.6M · quality 56.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$44M
P/E
N/A
•EV/EBITDA
N/A
•ROE
1.2%
↑Gross Margin
-207.0%
↓Debt/Equity
0.39
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2015–2025 · 10 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-7376.1%
FCF / Net income
-13.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $71000.0 · net income $401000.0 · FCF $-5.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||
| Revenue | $71000.00 | $71000.00 | $3.0M | $2.5M | $377000.00 | $500000.00 | — | — | — | — | — | — |
| Net Income | $401000.00 | $401000.00 | $39.8M | $-64.2M | $-89.0M | $-50.3M | $-34.3M | $-16.5M | $-18.0M | $-9.5M | $-5.7M | $-1.8M |
| EBITDA | $-2.3M | $-2.3M | $29.7M | $-75.7M | $-99.5M | $-54.2M | — | — | — | — | — | — |
| EPS | -5.63 | -5.63 | 15.00 | -274.80 | -450.90 | -292.50 | — | — | — | — | — | — |
| Gross Margin | -207.0% | -207.0% | -61.6% | -161.8% | -858.6% | -17.0% | — | — | — | — | — | — |
| Operating Margin | -30126.8% | -30126.8% | -1481.7% | -2805.7% | -24161.0% | -10878.6% | — | — | — | — | — | — |
| Net Margin | 564.8% | 564.8% | 1328.6% | -2617.3% | -23602.9% | -10069.4% | — | — | — | — | — | — |
| Balance Sheet | ||||||||||||
| Debt/Equity | 0.39 | 0.39 | -12.77 | -0.91 | -3.78 | — | — | — | — | — | — | — |
| Current Ratio | 0.17 | 0.17 | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||
| Free Cash Flow | $-5.2M | $-5.2M | $-33.6M | $-52.3M | $-72.5M | $-42.1M | $-22.0M | $-13.4M | $-8.8M | $-6.6M | — | — |
| Returns | ||||||||||||
| ROE | 1.2% | 1.2% | -1594.8% | 119.2% | 919.2% | -81.6% | -1807.8% | 430.4% | 776.3% | 334.2% | 1771.1% | -280.3% |
| Valuation | ||||||||||||
| P/E | — | — | 1.35 | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | — | — | 1.29 | — | — | — | — | — | — | — | — | — |
| P/B | 0.12 | 0.12 | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||
| Revenue Growth | -97.6% | -97.6% | 22.1% | 550.4% | — | — | — | — | — | — | — | — |
| EPS Growth | -137.5% | -137.5% | 105.5% | 39.1% | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-65.9%
Start / end P/E
n/dx → n/dx
EPS bridge
15.00 → -5.63
Residual
-65.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.